

# Avner Reshef

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3987562/publications.pdf>

Version: 2024-02-01

46  
papers

2,837  
citations

279701

23  
h-index

243529

44  
g-index

49  
all docs

49  
docs citations

49  
times ranked

1281  
citing authors

#	ARTICLE	IF	CITATIONS
1	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1961-1990.	2.7	153
2	Prodromes as predictors of hereditary angioedema attacks. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1309-1312.	2.7	2
3	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>World Allergy Organization Journal</i> , 2022, 15, 100627.	1.6	37
4	Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2022, 399, 945-955.	6.3	28
5	Effects of Continuous Plasma-Derived Subcutaneous C1-Esterase Inhibitor on Coagulation and Fibrinolytic Parameters. <i>Thrombosis and Haemostasis</i> , 2021, 121, 690-693.	1.8	9
6	The Enigma of Prodromes in Hereditary Angioedema (HAE). <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 15-28.	2.9	9
7	Biomarkers in Hereditary Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 404-415.	2.9	10
8	New Instrument for the Evaluation of Prodromes and Attacks of Hereditary Angioedema (HAE-EPA). <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 29-39.	2.9	5
9	Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 61, 84-97.	2.9	16
10	Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1392-1396.	1.1	0
11	Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeXES study. <i>Clinical and Translational Allergy</i> , 2021, 11, e12035.	1.4	22
12	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 901-911.	2.0	43
13	Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020, 33, 136-141.	0.3	10
14	Definition, aims, and implementation of GA <sup>2</sup> LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2115-2123.	2.7	29
15	Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 8.	0.9	16
16	Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children. <i>Pediatric Allergy and Immunology</i> , 2019, 30, 562-568.	1.1	18
17	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1793-1802.e2.	2.0	58
18	A Structured Gradual Exposure Protocol to Baked and Heated Milk in the Treatment of Milk Allergy. <i>Journal of Pediatrics</i> , 2018, 203, 204-209.e2.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1671-1678.e2.	2.0	39
20	Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1091-1097.	2.0	9
21	Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. New England Journal of Medicine, 2017, 376, 1131-1140.	13.9	169
22	Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet, The, 2017, 390, 1595-1602.	6.3	55
23	Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks. Allergy and Asthma Proceedings, 2017, 38, 456-461.	1.0	8
24	Hereditary angioedema: A call for collective terminology. Allergy and Asthma Proceedings, 2016, 37, 14-14.	1.0	0
25	Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 464-473.e4.	2.0	48
26	The Story of Angioedema: from Quincke to Bradykinin. Clinical Reviews in Allergy and Immunology, 2016, 51, 121-139.	2.9	38
27	Impact of an extended challenge on the effectiveness of $\beta$ -lactam hypersensitivity investigation. Annals of Allergy, Asthma and Immunology, 2016, 116, 329-333.	0.5	28
28	Recombinant Human-C1 Inhibitor Is Effective and Safe for Repeat Hereditary Angioedema Attacks. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 417-423.	2.0	32
29	Sustained Response Following Acute Treatment Of Hereditary Angioedema Attacks With Recombinant Human C1 Esterase Inhibitor. Journal of Allergy and Clinical Immunology, 2014, 133, AB37.	1.5	1
30	Case Title: 45 year-old male with recurrent angioedema: WAO international case-based discussions. World Allergy Organization Journal, 2014, 7, 2.	1.6	2
31	Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Annals of Allergy, Asthma and Immunology, 2014, 112, 163-169.e1.	0.5	70
32	C1-INH concentrate for treatment of acute hereditary angioedema: a pediatric cohort from the I.M.P.A.C.T. studies. Pediatric Allergy and Immunology, 2013, 24, 54-60.	1.1	32
33	The prophylaxis of hereditary angioedema attacks with recombinant human C1 inhibitor: who will take advantage of the individualized treatment approach?. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1207-1209.	2.7	4
34	Signs and symptoms preceding acute attacks of hereditary angioedema: Results of three recent surveys. Allergy and Asthma Proceedings, 2013, 34, 261-266.	1.0	44
35	Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Annals of Allergy, Asthma and Immunology, 2011, 107, 529-537.e2.	0.5	187
36	Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity. Allergy and Asthma Proceedings, 2011, 32, 36-42.	1.0	10

#	ARTICLE	IF	CITATIONS
37	HAE international home therapy consensus document. Allergy, Asthma and Clinical Immunology, 2010, 6, 22.	0.9	149
38	2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy, Asthma and Clinical Immunology, 2010, 6, 24.	0.9	443
39	Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema. New England Journal of Medicine, 2010, 363, 532-541.	13.9	477
40	Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacks. Annals of Allergy, Asthma and Immunology, 2010, 105, 149-154.	0.5	31
41	Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. Journal of Allergy and Clinical Immunology, 2009, 124, 801-808.	1.5	311
42	Angiotensin-converting enzyme inhibitor-induced angioedema in a community hospital emergency department. Annals of Allergy, Asthma and Immunology, 2009, 103, 502-507.	0.5	47
43	Hereditary angioedema: new hopes for an orphan disease. Israel Medical Association Journal, 2008, 10, 850-5.	0.1	13
44	The Hypereosinophilic Syndrome Associated with CD4 <sup>+</sup> CD3 <sup>+</sup> Helper Type 2 (Th2) Lymphocytes. Leukemia and Lymphoma, 2001, 42, 123-133.	0.6	54
45	Immunogold probe for the light-microscopic phenotyping of human mast cells and basophils. Journal of Immunological Methods, 1987, 99, 213-219.	0.6	14
46	A rapid Percoll technique for the purification of human basophils. Journal of Immunological Methods, 1987, 105, 107-110.	0.6	48